Lack of 'appropriately assessed' patient-reported outcomes in randomized controlled trials assessing the effectiveness of interventions for rosacea

British Journal of Dermatology

Volumn 168, Issue 2, 2013, Pages 442-444

  Van Zuuren, E J ^a   Fedorowicz, Z ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMA INTERNATIONAL UNIVERSITY   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; CYCLOSPORIN; DOXYCYCLINE; METRONIDAZOLE; PIMECROLIMUS; RILMENIDINE; TETRACYCLINE;

CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROSACEA;

HUMANS; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROSACEA; TREATMENT OUTCOME;

EID: 84873116140     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11148.x     Document Type: Letter

References (8)

1. van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev 2011; 3: CD003262.
2. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0, 2011 edn. Available at: http://www.cochrane-handbook.org (last accessed 13 July 2012).
3. The GRADE Working Group. GRADE Handbook For Grading Quality of Evidence and Strength of Recommendation. Version 3.2 (, Schünemann H, Brożek J, Oxman A, eds), 2009. Available at: http://www.cc-ims.net/gradepro (last accessed 13 July 2012).
4. Schechter BA, Katz RS, Friedman LS,. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009; 26: 651-9.
5. Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007; 156: 728-32.
6. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010; 63: 737-45.
7. Aksoy B, Altaykan-Hapa A, Egemen D, et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010; 163: 719-25.
8. Elewski BE, Draelos Z, Dréno B, et al. Rosacea-global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25: 188-200.